Tweet
Hi everyone. I'm working on a small fish genome and want to know if anyone is having any success using the new fast flow cells for HiSeq that give >100bp reads as input along with a 3000bp mate pair read as the input for allpaths rather than making the 180bp library. The fast flow cells generate single reads rather than paired reads which is why I'm not sure if this will work. Any input is appreciated especially if you have tried this.
-
-
That is not correct. Rapid mode flowcells can generated paired-end reads.Originally posted by troendle View Post -
Yes they can produce paired end reads but the library that we are attempting to work from is a 450bp library so they would not be overlapping. What we want to know is if allpaths can handle non-paired reads, or if we need to go ahead and make the 180bp library.Comment
-
Ok. Your original post was not clear.
You may want to consider running on MiSeq with the new v.3 kits. That can give you 2 x 300 bp reads.Comment
-
Kheloyaar: The Complete Guide to Kheloyaar Loginand Kheloyaar ID
The online gaming industry has transformed the way people enjoy digital entertainment. As technology continues to improve, players are looking for platforms that offer convenience, security, and a seamless user experience. Kheloyaarhas gained attention among users who value an easy-to-use platform, quick account access, and a simple registration process.
Whether you're exploring Kheloyaar for the first time or want to understand...Yesterday, 09:27 PM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...Yesterday, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment